Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jul 6th, 2026

LECO_Weekly-Healthcare-News_7-6-2026Download

Healthcare Weekly News and Deals –July 6th, 2026

  1. Select Medical Holdings Corporation (formerly NYSE: SEM) has completed a $3.9 billion management buyout led by Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe. Select Medical (NYSE: SEM) completed its acquisition by a consortium led by Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe at $16.50 per share, valuing the healthcare operator at approximately $3.9 billion. The price represents an 18% premium over SEM’s unaffected price as of November 24, 2025, and a 25% premium to the 90-day VWAP. WCAS, founded in 1979, focuses on healthcare and technology and has managed more than $33 billion in committed capital. The insider-led structure lets management pursue a concentrated rehabilitation strategy free of quarterly earnings pressure; SEM was delisted from the NYSE on July 1, 2026. (Link)
  2. Blue Owl Capital Inc. (NYSE: OWL) has completed the acquisition of Sila Realty Trust, Inc. (formerly NYSE: SILA) in an all-cash transaction valued at approximately $2.4 billion to expand its Real Assets platform. Blue Owl Capital (NYSE: OWL) announced its managed funds completed the acquisition of Sila Realty Trust, a net lease REIT focused on healthcare properties. The all-cash deal was valued at approximately $2.4 billion at $30.38 per share, a 19% premium to Sila’s April 17, 2026 close and a 25.6% premium to the 30-day VWAP. Sila stockholders approved the merger with more than 98% of votes cast in favor, and the stock was delisted. For Blue Owl (NYSE: OWL), which manages $315 billion in assets, the acquisition adds Sila’s 137 healthcare properties across 65 markets, deepening exposure to durable, essential real estate. (Link)
  3. BridgeBio Pharma, Inc. (NASD: BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street with participation from HealthCare Royalty, a business of KKR (NYSE: KKR). BridgeBio Pharma (NASD: BBIO) entered an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR (NYSE: KKR), to invest up to $1 billion in newly issued convertible preferred equity. Sixth Street funded $800 million as lead investor, with HealthCare Royalty funding $133.9 million at closing. The terms favor BridgeBio: a 7.00% initial dividend payable in kind or cash, an initial conversion price of $137.79 (over a 100% premium to the 30-day VWAP), stepping to $153.10 after year five, with permanent equity and no holder redemption. The capital funds Attruby’s growth and three planned launches. (Link)
  4. PACS Group, Inc. (NYSE: PACS) has agreed to acquire the operations of 34 skilled nursing facilities across six western states from Eduro Healthcare to broaden its post-acute platform. PACS Group (NYSE: PACS) entered a definitive agreement to acquire the operations of 34 skilled nursing facilities across six western states from Eduro Healthcare, a family-owned operator with nearly 20 years of history. The operations span Texas (22), Montana (six), South Dakota (three), and one each in New Mexico, North Dakota, and Utah, comprising 3,633 skilled nursing beds. The deal reflects PACS’s aggressive, acquisition-driven strategy that has propelled its market capitalization to $6.32 billion, though it also adds operational complexity and regulatory scrutiny that investors are weighing. CEO Jason Murray emphasized aligned operating models built on empowering local leadership. (Link)
  5. National HealthCare Corporation (NYSE American: NHC) has acquired 32 skilled nursing facilities and three independent living facilities from National Health Investors, Inc. (NYSE: NHI) for $560 million to convert leased assets into owned real estate. National HealthCare Corporation (NYSE American: NHC) completed the $560 million acquisition of 32 skilled nursing facilities and three independent living facilities from National Health Investors, Inc. and its affiliates, assets NHC had operated since a 1991 Master Lease. The strategic logic is ownership economics: management said the deal is expected to be accretive to earnings and cash flow, and CEO Steve Flatt framed owning versus leasing as yielding stronger long-term investor returns. NHC (NYSE American: NHC) shares have surged over 101% in the past year, trading near a 52-week high, with 12 consecutive years of dividend increases. The seven-state portfolio deepens NHC’s owned footprint across the Southeast. (Link)
  6. United Therapeutics Corporation (NASD: UTHR) has acquired Thymmune Therapeutics, Inc. for $140 million in cash plus up to $160 million in milestones to expand its regenerative medicine pipeline. United Therapeutics (NASD: UTHR) acquired preclinical biotech Thymmune Therapeutics, paying $140 million in cash subject to post-closing adjustments, with former equityholders eligible for up to $160 million in earn-outs tied to clinical and regulatory milestones through 2031. The structure ties the bulk of upside to performance, limiting UTHR’s downside on an early-stage asset. United Therapeutics reported $1.28 billion in cash as of March 31, 2026, comfortably funding the deal. Strategically, the acquisition strengthens UTHR’s regenerative medicine portfolio and supports its long-term strategy to expand transplantable organ supply, complementing its UThymoKidney program and adding lead candidate THY-100 for congenital athymia. (Link)
  7. GTCR-backed Experity has acquired Exdion Healthcare to accelerate AI-driven revenue cycle management automation for on-demand care. Experity, the on-demand healthcare technology platform used by nearly half of all U.S. urgent care clinics, acquired Exdion Healthcare, an AI-driven SaaS company specializing in the patient chart-to-cash lifecycle. The deal reflects sponsor GTCR’s vertical-integration playbook: Experity is backed by GTCR, a Chicago private equity firm, whose urgent-care strategy has been to own the EMR, practice management, billing, and analytics layers. GTCR Principal Radu Cret said the combination reflects the firm’s Leaders Strategy, scaling differentiated AI capabilities into a unified platform. Founded in 1980, GTCR has invested more than $35 billion in over 300 companies and manages approximately $45 billion in equity capital. Exdion’s insurance-focused affiliate was excluded. (Link)
  8. U.S. Physical Therapy, Inc. (NYSE: USPH) Acquires 12-Clinic Physical Therapy Practice in New State Expansion. U.S. Physical Therapy, Inc. (NYSE: USPH) announced the acquisition of a 12-clinic physical therapy practice effective July 1, 2026, acquiring a 67% equity interest (sellers retain 33%). The practice generates ~112,000 annual visits and $12 million in revenue, expanding USPH’s footprint to 45 states. The add-on aligns with USPH’s growth strategy of partnering with high-quality local operators while leveraging national scale in outpatient PT and industrial injury prevention. COO-West Graham Reeve highlighted alignment in clinical excellence and community relationships. This continues USPH’s disciplined M&A approach in a fragmented market. (Link)
  9. An affiliate of Peak Rock Capital has completed the acquisition of Asembia LLC from the Irene family to expand its healthcare portfolio through technology investment and add-on acquisitions. An affiliate of Peak Rock Capital, a middle-market private investment firm, completed the acquisition of Asembia LLC and its related entities, a specialty-pharma commercialization platform offering HUB services, specialty distribution, data services, pharmacy software, and GPO solutions. Peak Rock makes investments in the range of $50 million to $1.5 billion. The thesis is founder-partnership plus buy-and-build: Managing Director Spencer Moore said Peak Rock will invest in technology, capabilities, and marketing while pursuing complementary acquisitions to support accelerated growth. CEO Anthony DiSimone framed the deal as demonstrating Peak Rock’s commitment to founder-owned businesses with strong growth potential in resilient, technology-enabled healthcare. (Link)
  10. Gainline Capital Partners’ portfolio company M&M International has acquired KC Tech to expand its medical-grade tubing manufacturing capabilities. Gainline Capital Partners announced that its portfolio company M&M International, a manufacturer of precision-engineered stainless-steel tubing serving the medical device market, acquired KC Tech, a fellow manufacturer also focused on that market. This is a classic private-equity add-on: Gainline acquired M&M in July 2024 and installed a U.S.-based management team to support growth through organic expansion and strategic acquisitions. Gainline partner Rob Dellinger said the buy-and-build plan was in place from the outset, with KC Tech the next step. Gainline invests in U.S.-based middle-market companies, prioritizing first-institutional-capital partnerships; financial terms were not disclosed. The deal adds larger-diameter tubing to M&M’s portfolio. (Link)
  11. Martis Capital Management has acquired a majority stake in Deerfield Group from Edgewater Funds, with founders and management retaining significant ownership, to expand its healthcare marketing platform. Martis Capital Management, a middle-market healthcare private equity firm, acquired a majority equity stake in Deerfield Group, a marketing, communications, and media partner for healthcare and life sciences. Financial terms were not disclosed, and Deerfield’s founders and management team retain significant ownership. The deal marks a transition from prior investor Edgewater Funds, during which Deerfield grew revenue more than 30 percent annually since 2017. Managing Partner Mario Moreno cited Deerfield’s differentiated platform at the intersection of healthcare marketing, media, and technology. Since 2011, Martis has raised more than $2.2 billion from institutional clients for North American middle-market healthcare. (Link)
  12. Momentum Life Sciences has received a strategic growth investment from Parthenon Capital to accelerate its specialty-therapy commercialization platform and fund acquisitions. Momentum Life Sciences, a commercialization platform offering patient- and provider-facing solutions for specialty therapy initiation and adherence, announced a strategic investment from Parthenon Capital, a growth-oriented private equity firm. Financial terms were not disclosed, and Momentum’s existing leadership team will continue as significant shareholders. The structure is a management-aligned growth recapitalization: the capital will accelerate Momentum’s growth strategy and fund strategic acquisitions. Parthenon Partner Dan Killeen cited therapy adoption and adherence as acute, underserved challenges and a compelling opportunity to expand across the commercialization ecosystem. Parthenon, with offices in Boston, San Francisco, and Austin, has particular expertise in healthcare and technology services. (Link)
  13. Cathay Capital has launched and invested in Ascendia Autism Care, with Gladstone Capital Corporation (NASD: GLAD) as a capital partner, to expand access to evidence-based ABA therapy. Cathay Capital launched Ascendia Autism Care, a platform expanding access to evidence-based Applied Behavior Analysis therapy, beginning with a founding affiliate operating 20 centers across eight states. Cathay’s investment is sized to fund both the founding transaction and substantial growth capital, though financial terms were not disclosed. Crucially, Gladstone Capital Corporation (NASD: GLAD) was a capital partner in the transaction. The thesis targets an acute supply-demand gap; Cathay VP Jackson Catalano cited significant unmet need and the benefits of early intervention. Cathay Capital, founded in 2007, now manages more than $5.5 billion in assets, and plans de novo expansion plus school-based channels over 24 months. (Link)
  14. OpenLoop has acquired Y Combinator-backed Hey Revia, founded by Shaun Wei and David Zhu, to expand its AI-powered telehealth communications infrastructure. OpenLoop, an Iowa-based infrastructure telehealth platform, acquired Hey Revia, a Y Combinator-backed AI voice and communication platform automates healthcare operations such as insurance verification, prior authorizations, and pharmacy coordination. OpenLoop will integrate Hey Revia’s offerings into Launchpad, its self-serve platform for launching branded telehealth services, compressing client onboarding. Cofounders Shaun Wei and David Zhu join OpenLoop as EVP of engineering and senior director of engineering, respectively. The transaction extends OpenLoop’s acquisitive push following its earlier purchase of food-as-medicine platform Season Health. (Link)
  15. INVO Fertility, Inc. (NASD: IVF) has acquired the remaining stake in HRCFG from Karen Hammond, Lisa Ray, and Nicholas Cataldo for $175,001 to take full control of its Birmingham, Alabama fertility clinic. INVO Fertility (NASD: IVF) entered a Membership Interest Transfer Agreement to acquire 100% of HRCFG, gaining full control of its Birmingham, Alabama fertility clinic. The structuring is highly deferred and cash-flow-funded: the $175,001 consideration includes $1 at closing, $48,000 paid pro rata in equal monthly installments over nine months starting October 2026, and $127,000 drawn from HRCFG’s own free cash flow. For INVO (NASD: IVF), the appeal is consolidation—the company will consolidate the Alabama clinic’s results prospectively—converting a partial interest into a wholly owned revenue stream with minimal upfront capital outlay. Sellers will provide transition services for about four months and support for 12 months thereafter. (Link)
  16. Clarivate Plc (NYSE: CLVT) has announced the sale of its Life Sciences & Healthcare segment for $600 million to reduce leverage and refocus on its Academia & Government and Intellectual Property markets. Clarivate Plc (NYSE: CLVT) announced it has agreed to sell its Life Sciences & Healthcare segment for $600 million. The divestiture caps a process launched in February 2026, when Clarivate said a sale would allow further emphasis on its Academia & Government and Intellectual Property markets and that proceeds would strengthen its balance sheet through reduced leverage. The strategic driver is debt: Clarivate carries roughly $4.6 billion in long-term debt at a net leverage ratio of 7.7x trailing EBITDA, and the segment generated $389.8 million in 2025 revenue, its smallest at about 16% of the total. The acquirer was not identified in the sources available at the time of writing. (Link)
  17. Klick Health, backed by Linden Capital Partners and GIC, has acquired Oxford PharmaGenesis to expand its scientific-to-commercial capabilities for life sciences clients. Klick Health struck its third takeover in 18 months, acquiring UK-based Oxford PharmaGenesis to expand global reach and deepen scientific expertise. The deal follows a capital-backed roll-up strategy: months after acquiring Ward6’s Singapore operations, Klick received growth investment from Linden Capital Partners and GIC to accelerate expansion, and one year later made Oxford PharmaGenesis its biggest acquisition yet. The rationale is capability convergence—deepening Klick’s scientific expertise while expanding real-world evidence and health economics and outcomes research capabilities—positioning the combined firm against other private-equity-backed groups scaling in life sciences communications. Financial terms were not disclosed. (Link)
  18. Pacira BioSciences (NASD: PCRX) Agrees to Divest iovera° Business to Zimmer Biomet for Up to $140 Million. Pacira BioSciences, Inc. (NASD: PCRX) has agreed to divest its iovera° cryoneurolysis business to Zimmer Biomet Holdings, Inc. (NYSE: ZBH) for up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones through 2031. The move supports Pacira’s 5×30 strategy and transition to a pure-play innovative biopharmaceutical company focused on non-opioid pain therapies. Zimmer Biomet, a global medical technology leader, gains a complementary drug-free pain management device with established adoption and spasticity program upside. The transaction includes a transition services agreement and is expected to close in Q3 2026. (Link)
  19. ClearOne (NASD: CLRO) Enters Merger Agreement with Vivani Subsidiary Cortigent to Create Neurostimulation Public Platform ClearOne, Inc. (NASD: CLRO) has entered a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. (NASD: VANI). The deal includes a concurrent $10–15 million financing. Upon closing, the combined entity will operate as Cortigent Holdings, Inc. (expected ticker: CRGT), with Vivani owning a majority stake. Cortigent is developing precision neurostimulation implants (including the Orion cortical system with FDA Breakthrough Device Designation) for vision restoration and stroke recovery. The transaction provides Cortigent a public listing and growth capital while positioning the combined company in the high-potential neurotechnology space. Expected close in Q3 2026. (Link)
  20. Corten Capital has acquired Beacon Intelligence from the Hanson Wade Group, with Ampersand Capital Partners investing as a minority co-investor, to accelerate life sciences R&D intelligence. Corten Capital completed its acquisition of Beacon Intelligence from the Hanson Wade Group, with Ampersand Capital Partners investing alongside Corten as a minority co-investor, establishing Beacon as a fully independent company. The strategic aim is scale for a proprietary data platform: the investment gives Beacon resources to deepen coverage, expand into new therapeutic areas, and accelerate product features. Beacon is the third investment from Corten Capital II, which closed in March 2024 with €680 million in capital commitments, and Corten is partnering with management led by CEO Rob Poolman and Chair Sati S. Sian. David Anderson, General Partner at Ampersand, will join the board. (Link)
  21. Prestige Consumer Healthcare Inc. (NYSE: PBH) Completes Acquisition of LaCorium Health and Prices $400 Million Senior Notes Offering. Prestige Consumer Healthcare Inc. (NYSE: PBH) has closed its previously announced acquisition of LaCorium Health, an Australian leader in therapeutic skincare products (Dermal Therapy®, Flexitol®, and Crampeze® brands) for approximately $150 million in cash. LaCorium generates ~$40 million in annual revenue and is expected to contribute ~$12 million in EBITDA post-synergies, with strong growth potential through category expansion and geographic reach. The deal was financed with cash on hand and existing credit facilities. Concurrently, Prestige priced a $400 million senior notes offering (6.25% due 2034) to refinance existing debt. The transaction bolsters Prestige’s international consumer healthcare portfolio. (Link)
  22. Byggmästare Anders J Ahlström Holding AB (Nasdaq Stockholm: AJA B) reported that its portfolio company Safe Life completed four acquisitions during Q2 2026, adding roughly €20 million in annual revenue. Byggmästare Anders J Ahlström Holding’s largest portfolio company, Safe Life, added approximately €20 million in annual revenue through four acquisitions in Q2 2026, enhancing its buy-and-build strategy. The acquisitions broaden Safe Life’s presence in Europe and North America and align with its shift toward recurring, subscription-based revenue. For the listed investor Byggmästaren (Nasdaq Stockholm: AJA B), the value creation is concentrated: it owns roughly 12% of Safe Life, which represents about 34% of reported NAV. With €15 million acquired in Q1 and €20 million in Q2, Safe Life added ~€35 million of acquired revenue in H1—covering 80–115% of the assumed annual pace in the analyst valuation framework. (Link)

Venture Deals and Other

  1. Flare Therapeutics Inc. has secured $85 million in an insider-led Series C financing led by Third Rock Ventures and Nextech Invest, with participation from Pfizer Ventures, Eli Lilly, Novartis, and others. Flare Therapeutics, a clinical-stage biotech targeting transcription factors, closed an $85 million Series C led by existing investors. The round was led by Third Rock Ventures and Nextech Invest and included Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, and Eventide Asset Management. The insider-led composition signals conviction from a syndicate that includes strategic pharma investors. Proceeds will advance Flare’s ARON degrader FX-111 to proof of concept and fund preclinical development of the ARON RIPTAC program, alongside the appointment of veteran executive Anna Protopapas as CEO to steer its prostate-cancer focus. (Link)
  2. Integral Privacy Technologies has raised $25 million in total funding from backers including Caffeinated Capital, GreatPoint Ventures, Array Ventures, LiveRamp Ventures, Haystack, and Venrex. Integral Privacy Technologies, a San Francisco-based developer of automated data privacy engineering and decentralized telemetry protection software, raised $25 million in total funding. Backers included Venrex, The General Partnership, Array Ventures, GreatPoint Ventures, LiveRamp Ventures, Haystack, Virtue Ventures, Also Capital, Caffeinated Capital, LifeX Ventures, Circle & Co, and WS Investments. The broad syndicate reflects investor appetite for privacy infrastructure tied to AI development. The company intends to use the funds to expand its privacy engineering and statistical methodology divisions, invest in continuous risk-assessment linkage infrastructure, and accelerate go-to-market operations across global AI development labs. Integral spent four years validating peer-reviewed disclosure methodologies across healthcare and life sciences. (Link)
  3. Pictor Holdings Inc. has secured a $7.5 million bridge round from existing investors to accelerate commercialization of its targeted proteomic platform. Pictor Holdings, a Carlsbad, California-based targeted proteomic platform company, closed a $7.5 million bridge round of growth capital supported by existing investors. The financing brings Pictor’s total capital raised to approximately $30 million and will fund expanded commercial partnerships, platform and manufacturing scale-up, and translational studies across human and animal health markets. The insider-only backing signals continuity of conviction ahead of a larger raise; as CFO Tim Shannon noted, existing-investor support reflects confidence in the platform and commercial model as the company advances toward a Series A. Pictor has launched seven commercial products and secured four strategic partnerships in its first U.S. year. (Link)
  4. Upside Lands $20M Series A to Solve the U.S. Housing Crisis for Healthcare. Upside, a housing stability platform purpose-built for healthcare, closed a $20 million Series A co-led by Aquiline and Flare Capital Partners with participation from 645 Ventures, Freestyle Capital, Triple Impact Capital, and Techstars. The company addresses housing instability—a major driver of healthcare costs—by pairing dedicated Care Guides with AI-supported housing orchestration and a proprietary affordable housing database. Operating across 10 states with partnerships including four of the largest national payers, Upside has achieved 90%+ enrollment, stabilization for more than half of members within 90 days, and up to 4x ROI within 12 months. Proceeds will support expansion across Medicaid, Medicare Advantage, and employer-sponsored markets. (Link)
  5. Lycia Therapeutics Raises $75 Million in Oversubscribed Series D Financing and Strengthens Leadership Team. Lycia Therapeutics, Inc., a clinical-stage biotechnology company developing LYTAC and cataLYTAC degraders targeting extracellular proteins for autoimmune, inflammatory, and allergic diseases, closed an oversubscribed $75 million Series D. The round was co-led by Janus Henderson Investors and Balyasny Asset Management with participation from Adage Capital Management, HBM Healthcare Investments, OrbiMed, and continued support from existing investors including Eli Lilly, Franklin Templeton, Invus, RTW Investments, and Venrock. Proceeds will advance lead programs LCA-0061 (IgE degrader for food allergy) and LCA-0321 (for Graves’ disease) toward early clinical proof-of-concept. The company also appointed Amy Bachrodt as Chief Financial Officer and promoted Karen Flick to General Counsel. (Link)
  6. Anodyne Nanotech Closes $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch into Phase I Clinical Trials. Anodyne Nanotech Inc., a clinical-stage biotechnology company developing transdermal delivery of large molecules via its HeroPatch microneedle platform, closed a $12.6 million Series A led by Velocity Partners VC and co-led by Evercurious VC, with participation from Relativity Healthcare Partners. Proceeds will advance ANN-101, a once-weekly GLP-1 patch for obesity, into Phase I trials, support manufacturing scale-up, and expand the platform for peptides, antibodies, and nucleic acids. The company is also developing combination patches (e.g., apelin/GLP-1) to address lean mass loss associated with GLP-1 therapies. New board member Vikram Lamba (ex-Zosano Pharma, Bayer) joined as part of the round. (Link)
  7. Ladder Health Raises $7 Million Seed to Address Pediatric Therapy Waitlist Crisis. Ladder Health, a virtual-first pediatric developmental care company, closed an oversubscribed $7 million Seed round led by Nina Capital with participation from Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, and others. The company delivers speech, occupational, physical, and feeding therapy through an AI-enabled platform that activates caregivers and extends care into the home. Ladder partners with health systems and pediatric practices to reduce wait times from months to days, currently operating in Massachusetts, North Carolina, and Maryland with plans for further expansion. The funding will support geographic growth and platform development. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 18th, 2026

LECO_Weekly-Healthcare-News_5-18-2026-1Download
  1. Boston Scientific Announces $1.5 billion Strategic Investment in MiRus LLC Boston Scientific Corporation (NYSE: BSX) announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC, a privately held company developing proprietary biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Announced May 18, 2026, the agreement includes an exclusive option to acquire MiRus’ SIEGEL™ Balloon Expandable TAVR system, with potential additional payments of up to $3 billion upon clinical and regulatory milestones. The nickel-free, rhenium-alloy valve features a smaller delivery sheath, precise placement, and promising early clinical results in the ongoing STAR pivotal trial. The investment strengthens Boston Scientific’s interventional cardiology portfolio in the rapidly growing aortic stenosis market. (Link)
  2. J.P. Morgan, KKR, BofA Securities, and Barclays led the $478.7 million initial public offering of GMR Solutions (NYSE: GMRS) at a revised price of $15 per share GMR Solutions (NYSE: GMRS), the largest provider of emergency medical services in the U.S., priced its IPO at $15 per share, raising $478.7 million. The offering was led by a major syndicate including J.P. Morgan and KKR, with the latter also providing a $500 million concurrent private placement to bolster the company’s balance sheet. GMR Solutions plans to use the IPO proceeds primarily to pay down its existing debt. Despite the offering price being lowered from initial expectations, the IPO values the company at approximately $3.4 billion. The deal highlights significant institutional interest in the stabilization and growth potential of essential emergency and transport healthcare services. (Link)
  3. Prestige Consumer Healthcare (NYSE:PBH) Announces Acquisition of LaCorium Health Prestige Consumer Healthcare Inc. has entered into a definitive agreement to acquire LaCorium Health, a leading Australian platform in therapeutic skin care, lip, foot, and skin treatments. Announced May 13–14, 2026 alongside fiscal results, the approximately $150 million cash deal adds a high-growth, asset-light international OTC portfolio with strong market positions and expected double-digit revenue growth. The acquisition enhances Prestige’s dermatological offerings and geographic diversification. (Link)
  4. Lumexa Imaging (NASD: LMRI) executed its growth strategy by adding four new centers through joint ventures with University of Pittsburgh Medical Center (UPMC) and Advocate Health Lumexa Imaging the addition of four new locations in 2026, advancing its strategy to expand in high-growth markets via strategic partnerships. The expansion includes entry into the Pennsylvania market through a joint venture with the University of Pittsburgh Medical Center (UPMC) and further growth in the Southeast with Advocate Health. These additions, consisting of two acquisitions and two de novo centers, bring Lumexa’s total to over 190 outpatient imaging centers. The company leverages these joint ventures for capital efficiency and repeatability, focusing on the sustained shift toward outpatient, lower-cost sites of care driven by an aging population. (Link)
  5. Coastal Medical Transportation Systems Acquires Alert Ambulance to Expand New England Regional Care Network Coastal Medical Transportation Systems (CMTS), a leading privately owned medical transportation provider in New England, has completed the acquisition of Alert Ambulance Service. Announced May 18, 2026, the deal further strengthens CMTS’s position as one of the largest and most comprehensive ambulance and medical transportation providers in the region, following its prior integration of Fallon and Lifeline Ambulance Services. The acquisition expands geographic coverage across Massachusetts, New Hampshire, and Rhode Island, increases fleet size to over 325 vehicles, and grows the combined workforce to nearly 1,500 clinicians and support staff. (Link)
  6. Wellgistics Health (NASD: WGRX) Accelerates Digital Health Expansion with Planned Acquisition of WellCare Today Wellgistics Health, Inc. announced a non-binding letter of intent to acquire WellCare Today, a remote monitoring company specializing in RPM, RTM, and CCM programs powered by Samsung Galaxy Watch technology. Announced May 14, 2026, the proposed ~$15 million transaction (including $3 million cash and performance-based earnout in preferred stock) will integrate WellCare Today’s HealthAssist® platform with Wellgistics’ MSO pilot through Kare Clinicals and its network of over 6,500 independent pharmacies. The combination aims to enhance patient engagement, medication adherence, chronic care management, and reimbursement opportunities through wearable-enabled remote monitoring. (Link)
  7. Lorient Capital entered a strategic growth partnership with PeterMD to accelerate the national expansion of its proactive Medicine 3.0 healthcare platform Lorient Capital, a private equity firm exclusively focused on healthcare, has made a strategic investment in PeterMD to scale its personalized “Medicine 3.0” platform. PeterMD specializes in precision medicine, offering customized hormone health, longevity, and sexual wellness treatments through advanced diagnostics and proactive care. Lorient Capital is deploying capital from its $500 million Healthcare Fund III to fuel PeterMD’s national growth, aiming to transform the traditional reactive healthcare model. The partnership focuses on enhancing clinical outcomes and operational efficiency as PeterMD seeks to expand its footprint and bring precision-based integrated medicine to a broader national patient base. (Link)
  8. Blackstone and KKR & Co. Inc. reached a restructuring deal to take over the dental firm Affordable Care after slashing its total debt by 70% Direct lenders Blackstone and KKR are set to take control of Affordable Care, one of the largest U.S. dental services providers, following a major debt restructuring. The deal involves the lenders in a $1.4 billion private credit structure swapping their debt for equity, effectively slashing the dental firm’s debt load by approximately 70%. This restructuring provides Affordable Care with a significantly improved balance sheet to manage its extensive network of dental practices. The move underscores the increasing trend of major private credit lenders like Blackstone and KKR transitioning from creditors to equity owners to stabilize and preserve value in distressed healthcare portfolios. (Link)
  9. Quince Therapeutics (NASDAQ: QNCX)  Acquires Orphai Therapeutics and Raises up to $187 Million in Private Placement to Advance Pulmonary Pipeline Quince Therapeutics, Inc. announced the acquisition of Orphai Therapeutics, bringing in LAM-001, an inhaled formulation of rapamycin (sirolimus) for rare pulmonary diseases including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Concurrently, Quince entered a private placement to raise up to $187 million ($115 million upfront + up to $72 million from warrants), led by Balyasny Asset Management with participation from a strong syndicate of healthcare investors. The combined proceeds are expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2 data readouts in 2027 and 2028.
  10. Orthopaedic Specialty Group and OrthoConnecticut Merge to Create Statewide Physician-Led Platform Powered by HOPCo Technology Partnership Orthopaedic Specialty Group (OSG) and OrthoConnecticut have officially merged, creating a dominant, physician-led musculoskeletal (MSK) care platform across Connecticut. The merger is bolstered by a strategic partnership with Healthcare Outcomes Performance Company (HOPCo), the global leader in MSK value-based care. While the organizations merge their clinical networks to improve patient access, HOPCo provides the digital infrastructure, including advanced analytics and care management tools, to optimize outcomes and reduce total care costs. This collaboration allows the unified practice to scale thoughtfully while preserving clinical autonomy and delivering high-quality orthopedic services closer to home for patients throughout the Connecticut. (Link)
  11. Sweetser merged with Common Ties Mental Health Services to create Maine’s largest provider of Certified Community Behavioral Health Clinic services Common Ties Mental Health Services, based in Lewiston, has officially merged with Sweetser to create a robust behavioral health network in Maine. This merger establishes Sweetser as the state’s largest provider of Certified Community Behavioral Health Clinic (CCBHC) services, integrating Common Ties’ regional expertise into Sweetser’s broad statewide platform. The investment focuses on streamlining mental health delivery, expanding free community training, and increasing access to specialized behavioral health services. By consolidating resources, the combined entity aims to build a more sustainable and accessible care model to address the rising mental health needs across Maine’s diverse and often underserved communities. (Link)
  12. Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom, a portfolio company of American Securities LEARN Behavioral, a leading autism therapy provider backed by Gryphon Investors, has acquired Little Leaves Behavioral Services from FullBloom. FullBloom is a portfolio company of American Securities and sold the division to refocus on its core educational services. Little Leaves operates 18 early-intervention centers across Maryland, Virginia, and Florida, which will now join LEARN’s extensive national network. This acquisition allows LEARN Behavioral to expand its density in the Mid-Atlantic and establish a larger presence in the Florida market. The deal represents a significant consolidation within the ABA (Applied Behavior Analysis) sector, focusing on scaling early-intervention services for children with autism. (Link)
  13. Arcadea Group expanded its mission-critical software presence in Brazil through the acquisition of hemotherapy and hospital software provider Sofis Arcadea Group, a long-term investor in high-quality software firms, has acquired Sofis, a Rio de Janeiro-based provider of healthcare software. Sofis specializes in mission-critical solutions for blood bank management (hemotherapy) and hospital ERP systems, serving over 300 institutions across Brazil. This acquisition marks Arcadea’s fourth investment in the Brazilian healthcare technology market. Arcadea plans to leverage its permanent capital base to support Sofis’ long-term product development and international expansion. By transitioning from a founder-owned model to one backed by Arcadea’s global resources, Sofis aims to modernize its platform and deepen its penetration into the complex Latin American healthcare technology landscape. (Link)
  14. Iterative Health Acquires Cardiology Research Sites from NextStage Clinical Research Iterative Health, a healthcare technology and services company focused on accelerating clinical research, has acquired three cardiology research sites from NextStage Clinical Research in Texas (Beaumont, Port Arthur, and Waco). Announced on May 14, 2026, with Bourne Partners serving as financial advisor, the deal expands Iterative Health’s elite site network and strengthens its capabilities in cardiovascular research — a therapeutic area affecting nearly half of U.S. adults. The sites bring experienced teams, strong community provider connections, and an active trial portfolio, enhancing patient access to innovative therapies while providing sponsors with high-performing, real-world research centers. (Link)
  15. HealthScape Advisors Acquires PayerAlly to Strengthen Pharmacy Benefit Management Capabilities HealthScape Advisors, a leading payer advisory firm and a Chartis company, has acquired PayerAlly, an independent pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization. Announced May 12, 2026 (with coverage extending through mid-May), the deal enhances HealthScape’s ability to help health plans and employers address rapidly rising prescription drug costs through integrated, clinically informed total cost-of-care solutions. PayerAlly’s expertise in PBM strategy complements HealthScape’s broader payer advisory platform, supporting more effective management of one of healthcare’s fastest-growing expense categories. (Link)
  16. NeuroVision Acquires Durin Life Sciences to Advance Neurodegenerative Diagnostics NeuroVision, a diagnostics company developing early detection tools for Alzheimer’s and other neurodegenerative diseases, has acquired Durin Life Sciences, a fellow diagnostics developer. Announced May 15, 2026, the deal adds Durin’s blood-based Duritect™ tests for early detection and monitoring of Alzheimer’s, Parkinson’s, and ALS. The combination accelerates NeuroVision’s platform for earlier, more accessible diagnosis and disease management, addressing critical gaps in neurodegenerative care. (Link)
  17. IKS Health Acquires ARAI Solutions to Accelerate Agentic AI Capabilities IKS Health, a global leader in care enablement and AI-driven clinical solutions, has acquired ARAI Solutions, a specialized AI management and technology company focused on biomedical knowledge graphs and clinical reasoning infrastructure. Announced May 13–14, 2026, the deal enhances IKS Health’s ability to build proprietary small language models and agentic AI systems for clinical, operational, and revenue cycle workflows. ARAI’s ontology layer and applied research expertise will improve the reliability, auditability, and efficiency of IKS’s AI platforms serving health systems nationwide. (Link)
  18. Signant Health Acquires Ametris to Create End-to-End eCOA and Digital Outcome Measures Platform Signant Health, a leading evidence generation company for clinical trials, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider specializing in wearable-derived clinical outcome measures. The deal integrates Signant’s eCOA (electronic Clinical Outcome Assessment) solutions with Ametris’ validated sensor-based technologies for objective measurement of physical activity and function. The combined platform will deliver multimodal evidence—patient-reported outcomes alongside continuous real-world data—simplifying complex trials, accelerating insights, and strengthening regulatory submissions, particularly in CNS and other therapeutic areas. (Link)
  19. iSpecimen Inc. (NASD: ISPC) Secures $2.5 Million Private Placement to Support Operations Amid 89% Annual Stock Decline iSpecimen Inc. finalized a $2.5 million private placement on May 11, 2026, to bolster working capital. The biospecimen marketplace provider, currently valued at $3.39 million, has seen its share price plummet 89% over the past year to $4.57. This funding follows a $5.5 million raise in late 2025, aimed at mitigating rapid cash burn. iSpecimen, which connects medical researchers with specimen providers, will use the proceeds for general corporate purposes as it navigates significant financial challenges and seeks to stabilize its market position. (Link)
  20. Blue Sea Capital supported One Physics in its strategic acquisition and partnership with Petrone Associates to expand its Northeast clinical services footprint One Physics, the largest outsourced medical physics services company in North America, has announced its 22nd acquisition with the addition of New York-based Petrone Associates. This strategic move, backed by growth-oriented private equity firm Blue Sea Capital, significantly strengthens One Physics’ presence in the New York City metropolitan market and Northern New Jersey. The partnership leverages One Physics’ national scale and Petrone’s established clinical reputation to provide comprehensive diagnostic and therapy medical physics, radiation safety, and dosimetry services. Blue Sea Capital, managing over $1.5 billion in assets, remains committed to accelerating One Physics’ industry leadership through continued regional consolidation. (Link)

Venture Deals and Other

  1. Sound Ventures, Alumni Ventures, Link Ventures, Redesign Health, and RRE Ventures invested $17 million in Anomaly Insights to address healthcare payer-provider information asymmetry. Anomaly Insights, an AI-powered payer intelligence firm, secured $17 million in funding led by Sound Ventures to combat the informational gap between healthcare payers and providers. The investment includes participation from RRE Ventures and Redesign Health, focusing on Anomaly’s real-time AI platform that identifies and corrects billing errors and payment inaccuracies. The company aims to reduce the massive administrative waste in the U.S. healthcare system by providing transparency in the claims process. This new capital will be used to enhance Anomaly’s machine learning models and scale its solutions across larger health systems and insurance networks to streamline payment cycles. (Link)
  2. McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures led a $26 million Series A for Branchlab to scale its AI-driven biopharma commercialization platform Branchlab raised $26 million in a Series A round led by McKesson Ventures to accelerate the growth of its Pathwai™ platform. The round, which included corporate venture backing from Sanofi Ventures, brings Branchlab’s total funding to $35 million. The company uses privacy-first AI to optimize the patient journey and enhance pharmaceutical commercialization, reporting a 70% increase in patient activation efficiency. Branchlab intends to use the capital to expand its engineering and data science teams in New York and Colorado. By providing real-time insights to biopharma brands, Branchlab aims to make pharmaceutical marketing more effective and patient-centric through advanced data analytics. (Link)
  3. AIX Ventures led a $2 million pre-Seed funding round for Chromie Health to develop its autonomous AI-powered hospital workforce management platform Chromie Health, a New York-based startup, secured $2 million in pre-Seed funding led by AIX Ventures to tackle the hospital staffing crisis. The company develops autonomous AI agents that automate complex administrative tasks and workforce scheduling without requiring deep IT integration. Chromie Health’s platform is designed to alleviate the burnout of clinical staff by handling the logistics of hospital operations through intelligent automation. The investment will support the development of additional “digital agents” capable of reasoning through clinical context and staffing needs. This seed capital positions Chromie Health to pilot its solutions across more health systems seeking to modernize their operational efficiency. (Link)
  4. Blueprint Equity, Villain Capital, Z21 Ventures, and Bienville Capital led a $14 million growth funding round for pediatric-focused AI operating system Develo Develo, an AI-native operating system for pediatric practices, raised $14 million in a funding round led by Blueprint Equity. The platform integrates clinical workflows, billing, and parent engagement into a single AI-driven ecosystem, currently serving hundreds of providers across 25 states. The capital will be used to accelerate the development of specialized AI tools, including automated charge capture and AI-assisted scribing for pediatricians. Develo aims to reduce the administrative burden that leads to physician burnout while improving the financial performance of independent pediatric practices. The investment highlights a growing trend toward specialty-specific AI platforms that address unique clinical and operational workflows. (Link)
  5. Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC backed Forus with $160 million to build its AI-powered pharmaceutical delivery network Forus, formerly known as Tandem, raised $160 million in a major funding round backed by top-tier venture firms including Thrive Capital and General Catalyst. The company is building an AI-powered infrastructure that connects doctors, pharmacies, and biopharma companies to streamline the drug fulfillment process. Forus automates the “last-mile” clinical steps, such as insurance authorizations, to ensure patients receive treatments faster. With five of the top ten global biopharma companies already utilizing the network, Forus plans to use the investment to expand its nationwide reach and further integrate its AI layer into existing physician and pharmacy workflows to eliminate treatment delays. (Link)
  6. Uncork Capital, Frist Cressey Ventures, Moxxie Ventures, and Coalition Operators provided $11.6 million in Seed funding for the launch of Knit Health’s clinical behavior AI Knit Health, a spin-out from UC Berkeley, launched with $11.6 million in Seed funding co-led by Uncork Capital and Frist Cressey Ventures. The company is developing a Large Clinical Behavior Model (LCBM) trained on real-world clinician decisions across 30 U.S. health systems. Knit Health’s AI agents are designed to handle triage, patient flow, and care coordination by learning from collective clinical experience rather than just static text. The funding will be used to scale its foundational intelligence layer and deploy AI agents that assist in high-stakes hospital environments. This investment reflects a shift toward “Action AI” that can reason and perform complex tasks in clinical settings. (Link)
  7. Salesforce Ventures, Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures raised $17.5 million in Series A funding for Optura’s AI governance platform Optura, a Nashville-based healthcare AI governance platform, secured $17.5 million in Series A funding led by Salesforce Ventures. The investment, which brings Optura’s total funding to $25 million, will support the expansion of its “Return on AI Investment” (ROAI) platform. Optura helps enterprise healthcare organizations, such as Independence Blue Cross, map fragmented data and measure the efficacy of their AI agents. The capital will be used to scale partnerships with LLM providers and grow its engineering teams. By providing a unified knowledge layer, Optura enables healthcare leaders to prioritize AI use cases based on actual operational readiness and projected business value. (Link)
  8. Norwest, Primary, Next Ventures, Constellation, and Scrub Capital led a $25 million financing round for Tokaido Health to launch its AI medication steerage platform. Tokaido Health emerged from stealth with $25 million in funding led by Norwest and Primary to address skyrocketing pharmacy costs for employers. The platform utilizes AI and behavioral economics to identify same-or-better medications that cost less, steering members toward high-value options like biosimilars. Tokaido layers on top of existing PBM stacks, allowing for a seamless integration without plan redesigns. The investment will be used to scale its concierge-style member outreach and expand its clinical reasoning engine. By focusing on site-of-care steerage and polypharmacy reconciliation, Tokaido aims to eliminate billions in wasted drug spending while improving the patient experience. (Link)
  9. Andera Partners, American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, and Anduril Investors led a $20 million Series D for Rivermark Medical Rivermark Medical, a urology-focused medical device company, raised $20 million in Series D funding led by Andera Partners. The financing will support the ongoing RAPID III pivotal clinical trial for the FloStent™ System, a non-surgical treatment for men with benign prostatic hyperplasia (BPH). The investment syndicate includes American Century Investments and Time BioVentures, focusing on bringing this reversible, office-based therapy to market. The FloStent is designed to be easily adjustable and tissue-preserving, offering a first-line alternative to more invasive surgical procedures. The capital will also be used to prepare for a U.S. commercial launch following expected regulatory approval. (Link)
  10. Aulis Capital led a $13.4 million Seed funding round for Shyld AI to accelerate the deployment of its autonomous AI-driven infection control solutions Shyld AI, a healthcare technology company, secured $13.4 million in Seed funding led by Aulis Capital to expand its active intelligence solutions for hospital facilities. Shyld AI develops autonomous physical agents that use AI and UV disinfection to reduce environmental contamination in high-risk areas like operating rooms. The funding will accelerate deployments across U.S. health systems and support the company’s expansion into regulated pharmaceutical manufacturing environments. By streamlining infection control and compliance without adding to the workload of hospital staff, Shyld AI aims to improve patient safety and operational efficiency. The investment marks a significant milestone in the adoption of autonomous hygiene agents in healthcare. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities
CLICK HERE